2.13
+0.15(+7.58%)
Currency In USD
| Previous Close | 1.98 |
| Open | 1.95 |
| Day High | 2.15 |
| Day Low | 1.95 |
| 52-Week High | 5.12 |
| 52-Week Low | 1.61 |
| Volume | 25,625 |
| Average Volume | 34,457 |
| Market Cap | 87.58M |
| PE | -1.61 |
| EPS | -1.32 |
| Moving Average 50 Days | 1.92 |
| Moving Average 200 Days | 3.04 |
| Change | 0.15 |
If you invested $1000 in Elutia Inc. (ELUT) since IPO date, it would be worth $146.9 as of July 02, 2025 at a share price of $2.13. Whereas If you bought $1000 worth of Elutia Inc. (ELUT) shares 3 years ago, it would be worth $320.3 as of July 02, 2025 at a share price of $2.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
New Evidence Supports the Value of Elutia’s Antibiotic-Eluting Platform for Implantable Devices
GlobeNewswire Inc.
Yesterday at 12:00 PM GMT
— The EluPro BioEnvelope findings demonstrate the bioactive properties and superior healing response compared to synthetic materials for cardiac implantable electronic devices (CIEDs) — GAITHERSBURG, Md., July 01, 2025 (GLOBE NEWSWIRE) -- Elutia In
Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method
GlobeNewswire Inc.
May 28, 2025 12:00 PM GMT
— Innovative approach accelerates new product development and testing —SILVER SPRING, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced th
Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio
GlobeNewswire Inc.
May 01, 2025 8:05 PM GMT
Move expected to drive both top-line growth and gross margin improvement SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today announced it